Literature DB >> 26763713

Utility of in-house fluconazole disk diffusion susceptibility testing in the treatment of candidemia.

David W Kubiak1, Dimitrios Farmakiotis2, Viktoria Arons3, Randy M Hollins3, Sara E Rostas3, Linda M Weiser4, Lindsey R Baden5, Francisco M Marty5, Sophia Koo6.   

Abstract

Among 302 first candidemia episodes, 210 (69.6%) were initially treated with an echinocandin or polyene (E/P) antifungal drug. In 137 (72.5%) patients with fluconazole-susceptible isolates, treatment was changed to fluconazole based on disk diffusion susceptibility testing. Clinical outcomes were not compromised in patients receiving E/P who were de-escalated to fluconazole for treatment of candidemia based on disk diffusion results.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Candidemia; Disk diffusion susceptibility testing; Fluconazole

Mesh：

Substances：

Year:  2015        PMID： 26763713      PMCID： PMC4917365          DOI： 10.1016/j.diagmicrobio.2015.11.018

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  13 in total

Review 1.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

2.  Early initiation of appropriate treatment is associated with increased survival in cancer patients with Candida glabrata fungaemia: a potential benefit from infectious disease consultation.

Authors:  Dimitrios Farmakiotis; A Kyvernitakis; J J Tarrand; D P Kontoyiannis
Journal:  Clin Microbiol Infect       Date:  2014-10-12       Impact factor: 8.067

Review 3.  The case for antifungal stewardship.

Authors:  Michelle R Ananda-Rajah; Monica A Slavin; Karin T Thursky
Journal:  Curr Opin Infect Dis       Date:  2012-02       Impact factor: 4.915

4.  The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.

Authors:  Ryan K Shields; M Hong Nguyen; Ellen G Press; Andrea L Kwa; Shaoji Cheng; Chen Du; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2012-07-02       Impact factor: 5.191

5.  Attributable mortality of nosocomial candidemia, revisited.

Authors:  Olafur Gudlaugsson; Shane Gillespie; Kathleen Lee; Jeff Vande Berg; Jianfang Hu; Shawn Messer; Loreen Herwaldt; Michael Pfaller; Daniel Diekema
Journal:  Clin Infect Dis       Date:  2003-10-08       Impact factor: 9.079

6.  Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.

Authors:  Barbara D Alexander; Melissa D Johnson; Christopher D Pfeiffer; Cristina Jiménez-Ortigosa; Jelena Catania; Rachel Booker; Mariana Castanheira; Shawn A Messer; David S Perlin; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

7.  FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia.

Authors:  Nicholas D Beyda; Julie John; Abdullah Kilic; Mohammad J Alam; Todd M Lasco; Kevin W Garey
Journal:  Clin Infect Dis       Date:  2014-05-30       Impact factor: 9.079

8.  Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program.

Authors:  Michael A Pfaller; Linda Boyken; Richard J Hollis; Jennifer Kroeger; Shawn A Messer; Shailesh Tendolkar; Daniel J Diekema
Journal:  Diagn Microbiol Infect Dis       Date:  2009-09       Impact factor: 2.803

9.  Comparison of results of fluconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program.

Authors:  M A Pfaller; K C Hazen; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

10.  Drug-resistant Candida glabrata infection in cancer patients.

Authors:  Dimitrios Farmakiotis; Jeffrey J Tarrand; Dimitrios P Kontoyiannis
Journal:  Emerg Infect Dis       Date:  2014-11       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.